To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...

Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial Over the past 15 years, the landscape ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover ...

Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the BREAKWATER trial. The study ...

Just nine months after announcing a massive plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money.

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.